Publications by authors named "P Vaflard"
Triple negative breast cancer (TNBC) is defined by the absence of expression of estrogen and progesterone receptors, as well as the absence of overexpression of HER2. Accounting for 10 to 15% of breast cancers, it remains characterized by an aggressive phenotype with an increased risk of early recurrence and overall survival less favorable compared to other subtypes. The challenges in management and therapeutic evolution are likely related to the demonstrated high biological heterogeneity of this subtype.
View Article and Find Full Text PDFBackground: Patients' expectations regarding medical information in advanced stages of cancer are still poorly understood. Tailoring information to advanced cancer patients is a subtle task. We developed a question prompt list (QPL) that serves as a patient-oncologist communication aid in France.
View Article and Find Full Text PDFBackground: Sacituzumab govitecan (SG) has been approved by FDA in April 2021 for pre-treated metastatic triple-negative breast cancer (mTNBC), following the ASCENT trial results.
Methods: We set up an ambispective bicentric cohort study to assess the real-world effectiveness and safety of SG in patients with mTNBC treated at Institut Curie Hospitals, with a focus on patients with brain metastases.
Results: This study included 99 patients treated through the French Early Access Program to SG from May 2021 to January 2023.
Aims: The purpose of this work was to assess failures in the advanced prescription of parenteral anticancer agents in an adult day oncology care unit with more than 100 patients per day.
Methods: An a priori descriptive analysis was carried out by using the risk matrix approach. After defining the scope in a multidisciplinary meeting, we determined at each step the failure modes (FMs), their effects (E) and their associated causes (C).
Article Synopsis
- Following the IMpassion130 trial, France launched an early access program allowing patients with PD-L1-positive advanced triple negative breast cancer to receive a combo of paclitaxel and atezolizumab, but it was discontinued after the negative IMpassion131 trial results.
- A multicentric analysis of 64 patients enrolled in the EAP showed a median progression-free survival of 4.1 months and overall survival of 17.9 months, with 28% having a positive response at 6 months.
- The use of corticosteroids before treatment was identified as a negative factor affecting progression-free survival, while no new safety signals were detected in this real-world study.